Wall Street Zen Upgrades Compass Therapeutics (NASDAQ:CMPX) to “Hold”

Compass Therapeutics (NASDAQ:CMPX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other research firms have also recently commented on CMPX. D. Boral Capital reiterated a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a report on Tuesday, January 6th. William Blair initiated coverage on Compass Therapeutics in a research note on Monday, January 5th. They set an “outperform” rating on the stock. Citigroup began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating for the company. Compass Point set a $10.00 price target on Compass Therapeutics in a report on Monday, October 6th. Finally, Canaccord Genuity Group began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They issued a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Trading Up 0.3%

NASDAQ CMPX opened at $6.40 on Friday. Compass Therapeutics has a 12 month low of $1.33 and a 12 month high of $6.49. The stock’s fifty day moving average price is $5.46 and its 200-day moving average price is $4.26. The stock has a market cap of $1.14 billion, a P/E ratio of -14.22 and a beta of 1.45.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. As a group, analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Russell Investments Group Ltd. boosted its holdings in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the last quarter. Creative Planning bought a new position in Compass Therapeutics in the second quarter worth approximately $30,000. Flagship Harbor Advisors LLC bought a new position in Compass Therapeutics in the fourth quarter worth approximately $32,000. Strs Ohio purchased a new position in shares of Compass Therapeutics during the 1st quarter worth $34,000. Finally, Apollon Wealth Management LLC bought a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.